AbbVie stock slips 0.87% to EUR 262.80 before Xetra
Published on 11/02/2026 at 08:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance and pipeline shape focus
- Third-quarter net revenue increased 10.3 percent to USD 17.404 billion.
- AbbVie raised its 2026 adjusted diluted EPS guidance to USD 13.95-13.99.
- Skyrizi, Rinvoq and neuroscience products remained key growth drivers, while the company advanced its immunology and oncology pipeline.
AbbVie stock traded at EUR 262.80 on Lang & Schwarz at 08:03 CET on Monday, November 2, 2026, 0.87 percent below the Xetra close of Friday, October 30, at EUR 265.10.
AbbVie’s latest quarterly release showed net revenue of USD 17.404 billion, up 10.3 percent from a year earlier. Adjusted diluted earnings per share reached USD 3.82. The company raised its full-year 2026 adjusted diluted EPS outlook to USD 13.95-13.99 from USD 13.76-13.96.
The company also lifted its quarterly cash dividend from USD 1.73 to USD 1.82 per share, with the higher payment scheduled to begin in February 2027. AbbVie said it had completed its acquisition of Apogee Therapeutics, adding assets in immunology and related disease areas.
In its third-quarter financial release, AbbVie reported that immunology revenue grew 16.3 percent and neuroscience revenue increased 19.4 percent, while aesthetics revenue declined 1.4 percent. The figures leave execution in established brands and progress in newer pipeline programs as central issues for investors.
Investors can follow the real-time quote of AbbVie stock during the European session.
The broader market backdrop is reflected in the S&P 500.
Further updates are available in more news and analyses on AbbVie stock.
